Zeltiq Aesthetics Inc news

   Watch this stock
Showing stories 1 - 10 of about 46   

Articles published

ZLTQ 17.90 -0.15 (-0.83%)
price chart
ZELTIQ Aesthetics Inc.: ZELTIQ Announces Conference Call and Webcast of ...
PLEASANTON, CA -- (Marketwired) -- 04/15/14 -- ZELTIQ� (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans ...
ZELTIQ Announces Conference Call and Webcast of First Quarter 2014 ...  MarketWatch
Related articles »  
CoolSculpting for thighs
The FDA clears Zeltiq Aesthetics' (ZLTQ +0.6%) entire suite of CoolSculpting applicators to treat thighs. Previously, it was approved to treat only the abdomen and flanks.
Hot on 'cool' thighs, Zeltiq wins FDA clearance for fat-chilling ...  San Francisco Business Times (blog)
ZELTIQ Announces FDA Clearance to Treat Thighs  Wall Street Journal
Related articles »  
Cantor Positive on FDA Approval of ZELTIQ Aesthetics' (ZLTQ) Thigh Area ...
ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ) is positive Monday after the company announced it has received U.S. Food and Drug Administration (FDA) clearance to treat the thigh area with its entire suite of applicators.
Insider Selling: Mark Foley Sells 7123 Shares of ZELTIQ Aesthetics Stock (ZLTQ)
Analysts expect that ZELTIQ Aesthetics will post $-0.36 EPS for the current fiscal year. Zeltiq Aesthetics, Inc operates as a medical device development company.
Zeltiq Aesthetics Gets FDA Clearance To Treat Thigh
(RTTNews.com) - Zeltiq Aesthetics Inc. ( ZLTQ ) announced it has received U.S. Food and Drug Administration or FDA clearance to treat the thigh area with its entire suite of applicators.
Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA ...
ZELTIQ Aesthetics Inc (NASDAQ:ZLTQ) CTO Leonard Debenedictis sold 10,071 shares of the stock on the open market in a transaction that occurred on Thursday, April 10th.
Related articles »  
ZELTIQ Aesthetics CTO Unloads $187421 in Stock (ZLTQ)
ZELTIQ Aesthetics presently has a consensus rating of �Buy� and a consensus price target of $23.11. Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive ...
ZELTIQ Aesthetics CTO Leonard Debenedictis Sells 10071 Shares (ZLTQ)  Zolmax
Worth Watching Stocks � Affymetrix, (NASDAQ:AFFX), ZELTIQ� Aesthetics ...  Techsonian (press release)
Related articles »  
Zeltiq Aesthetics (ZLTQ): Getting Past Emotion
Zeltiq Aesthetics (ZLTQ) is a case in point. This California-based company sells ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. This article ...
Related articles »  
Progenics Pharmaceuticals Inc Initiates Clinical Development And Zeltiq ...
Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) won Food & Drug Administration clearance to use the company's fat-chilling procedure for reducing fat on the thighs, said the company.
Insider Selling: ZELTIQ Aesthetics CFO Sells 5000 Shares of Stock (ZLTQ)
Analysts expect that ZELTIQ Aesthetics will post $-0.36 EPS for the current fiscal year. Zeltiq Aesthetics, Inc operates as a medical device development company.
ZELTIQ Aesthetics VP Sells $45411 in Stock (ZLTQ)  Mideast Time
Related articles »